Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.

被引：0
|
作者：
Leapman, Michael
Presley, Carolyn J.
Zhu, Weiwei
Soulos, Pamela R.
Adelson, Kerin B.
Boffa, Daniel J.
Gross, Cary Philip
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Yale Univ, New Haven, CT USA
[4] Yale Sch Med, Thorac Surg Sect, Dept Surg, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study
    Dietel, M.
    Savelov, N.
    Salanova, R.
    Micke, P.
    Bigras, G.
    Hida, T.
    Piperdi, B.
    Burke, T.
    Khambata-Ford, S.
    Deitz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S74 - S75
  • [32] Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and treatment (Tx) patterns in the real-world (RW) setting
    VanderWalde, A. M.
    Lee, J.
    Tolba, K.
    Ward, A.
    Cooper, M.
    Huang, R. S. P.
    Venstrom, J.
    Oxnard, G.
    Schrock, A. B.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1006 - S1007
  • [33] Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer
    Zhang, Xinke
    DeClue, Richard W.
    Herms, Lisa
    Yang, Mo
    Pawar, Vivek
    Masters, Elizabeth T.
    Ruisi, Mary
    Chin, Kevin
    Velcheti, Vamsidhar
    IMMUNOTHERAPY, 2021, 13 (18) : 1521 - 1533
  • [34] Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States
    Veluswamy, Rajwanth
    Hirsch, Fred R.
    Taioli, Emanuela
    Wisnivesky, Juan
    Strauss, Ross
    Harrough, Douglas
    Tang, Boxiong
    Barnes, Gisoo
    CANCER MEDICINE, 2022, 11 (22): : 4265 - 4272
  • [35] Clinical impact of 22C3 PD-L1 expression in non-small cell lung cancer.
    Okabe, Naoyuki
    Takagi, Hironori
    Suzuki, Hiroyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [36] Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.
    Wang, Weili
    Zhang, Chen
    Cheng, Liang
    Jin, Jianyue
    Kong, Fenq-Ming Spring
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [38] Companion and complementary diagnostics for PD-L1 expression assessment in non-small cell lung cancer.
    Anderson, Steven M.
    Horten, Bruce
    McCune, Bryan
    Paler, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] The real-world comparison of non-small cell lung cancer survival outcomes depending on immunotherapy treatment and PD-L1 expression level
    Ondrusova, Martina
    Suchansky, Martin
    Svidova, Sona VaNDOR
    Chowaniecova, Gabriela
    Mrinakova, Bela
    Sekeresova, Monika
    Juskanic, Dominik
    Ondrus, Dalibor
    Senitko, Michal
    NEOPLASMA, 2024, 71 (05)
  • [40] Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Peng Song
    Jingcheng Zhang
    Congcong Shang
    Li Zhang
    Scientific Reports, 10
12345